There are 126 drugs in clinical development for Alzheimer's disease and "every single one represents hope," according to Closing in on a Cure: 2017 Alzheimer's Clinical Trials Report. The report, released today by the Alzheimer's Drug Discovery Foundation (ADDF), identifies the drugs for Alzheimer's that have reached human clinical trials.

"Alzheimer's has too often been a story of failure," says Howard Fillit, MD, Chief Science Officer at the ADDF. "But this report shows a diverse group of promising drugs are nearing the finish line. The first disease-modifying treatment for Alzheimer's is likely in clinical trials right now. We are closing in."

While drugs targeting beta-amyloid (a protein that comprises the plaques common in Alzheimer's) remain the most prevalent, other drug targets such as inflammation, mitochondria, and neuroprotection are gaining ground. This broadening of targets is due in part to the efforts of the ADDF, which funds new approaches to treating Alzheimer's. Nearly 20% of the drugs now in clinical stages have received ADDF support.

Read the source article at PR Newswire